section name header

Information

Editors

KariPuolakka

Rheumatoid Arthritis

Essentials

  • If rheumatoid arthritis (RA) is suspected, the patient should be referred without delay to a rheumatology outpatient clinic.
    • RA as an immunological disorder may begin several years before the appearance of symptoms, which may, at first, be unspecific, making it impossible to distinguish incipient RA from other types of arthritis.
    • If there is inflammation in several, particularly small, joints, and rheumatoid factor and/or citrullinated peptide antibodies in blood, the patient probably has RA. Seronegative polyarthritis differs from seropositive polyarthritis as regards genetics and its more favourable prognosis, and it may prove in follow-up to be psoriatic arthropathy, for example.
    • ESR and CRP may be normal.
    • Systemic glucocorticoids interfere with the diagnosis and should therefore not be started in primary health care, but a glucocorticoid can be injected as first aid into inflamed joints.
    • New patients with symptoms of arthritis need to see a rheumatologist unless the diagnosis is evident and treatment can be provided on the primary care level, as is often the case with gout or reactive arthritis.
  • RA is a progressive, debilitating disease but effective medication started early can make more than half of newly diagnosed patients asymptomatic within six months.
  • The basic medication consists of a combination of methotrexate, sulfasalazine and hydroxychloroquine. Low glucocorticoid doses should be added to the regimen for at least a few months.
  • Inflamed joints should be treated with glucocorticoid injections.
  • RA not responding to combination drug therapy should be treated with biologicals biologicals or with a janus kinase (JAK) inhibitor.
  • Physical exercise will improve the patient's functional ability and reduce the risk of cardiovascular disease.

Epidemiology

  • About 40 adults per 100 000 per year develop RA.
  • The age at onset is most commonly 65-70 years but two in three of those developing the disease are younger than 65 years old.
  • Two in three patients are women.
  • Some people are genetically susceptible to RA.
  • Smoking doubles the risk of the disease.

Symptoms

  • The onset of RA is usually insidious.
  • Morning stiffness, tender and swollen joints are typical.
  • Proximal interphalangeal and metacarpophalangeal joints, wrists, and balls of the feet are most commonly affected but basically any joint may become inflamed.
  • Fatigue, malaise and mild fever may occur as systemic symptoms.

Investigations in primary care

  • See the article Clinical examination of patients with joint inflammation in primary health care Clinical Examination of Patients with Joint Inflammation in Primary Health Care.
  • Palpation can be used to find out whether a patient with joint symptoms has arthritis.
  • An inflamed joint is characterized by soft swelling, tenderness, pain on movement and a limited range of motion.
    • Fist closure is often limited in patients with inflammation of small finger joints or with flexor tenosynovitis.
    • Tenderness on lateral squeezing of the knuckles or balls of the feet suggests arthritis.
    • It may be difficult to distinguish arthritis from osteoarthritis. In fingers, osteoarthritis occurs in the distal or proximal interphalangeal joints, RA in proximal interphalangeal and metacarpophalangeal joints. Patients with osteoarthritis may develop rheumatoid arthritis.
  • Laboratory tests: ESR, CRP, basic blood count with platelets, RF, anti-CCP antibodies
    • ALT, ALP, creatinine, urate, Borrelia antibodies, chemical screening of urine, ANAs, antibodies to diagnose reactive arthritis, as considered necessary (see Reactive arthritis > Diagnosis Reactive Arthritis).
  • If intra-articular injections are given, a synovial fluid sample should be taken at the same time for examination (synovial fluid leucocytes + differential count from synovial fluid, bacterial culture, possibly synovial fluid crystals), if fluid can be aspirated; see the article Investigation of Synovial Fluid.
    • In patients with arthritis, synovial fluid is cloudy, with a leucocyte count exceeding 2 000 × 106 /l.
    • Highly cloudy synovial fluid suggests bacterial arthritis, usually monoarthritis.
  • Imaging of patients with arthritis should mainly be performed at a rheumatology outpatient clinic.

Principles of drug treatment

  • RA should be diagnosed and medication begun at a rheumatology outpatient clinic.

Beginning of treatment Combination Therapy in Rheumatoid Arthritis, Methotrexate for Rheumatoid Arthritis, Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis, , , , Intra-Articular Steroids in the Knee for Rheumatoid Arthritis, , , , , , , , , , , Effects of Glucocorticoids on Radiological Progression in Rheumatoid Arthritis,

  • The basic medication for RA consists of a combination of methotrexate, sulfasalazine and hydroxychloroquine, unless contraindicated (e.g. renal failure, sulfa allergy). Methotrexate is the most effective component.
  • Low glucocorticoid doses (5-7.5 mg prednisolone or equivalent) should be combined with these.
    • Doses exceeding 7.5 mg increase the risk of adverse effects (osteoporosis, cataracts, diabetes, adrenocortical suppression).
  • Methotrexate should be given in doses of 15-25 mg once weekly. It is best tolerated and most effective when given by injection. The bioavailability of oral doses does not usually increase when exceeding doses of 15 mg/week. Methotrexate should be combined with 5 mg folic acid once weekly.
  • If combination therapy and methotrexate are contraindicated or the patient cannot tolerate methotrexate, a biological antirheumatic drug or JAK inhibitor should be started.
    • Women must not use methotrexate or leflunomide when planning to become pregnant or during pregnancy or breast-feeding.
  • Inflamed joints should be treated with glucocorticoid injections.
  • Other antirheumatic medication (leflunomide, azathioprine, ciclosporin, mycophenolate or cyclophosphamide) is rarely needed.
  • The decision on drug treatment should be made together with the patient.
    • Encouraging guidance is important for committing the patient to treatment.

Screening before starting to use immunosuppressive medication (such as methotrexate, biological agents, JAK inhibitors)

  • Before starting the treatment, infections such as tuberculosis (chest x-ray) and, in individual cases, viral hepatitis, should be excluded, a dental check-up performed and it should be confirmed that appropriate vaccinations have been administered.
  • Before starting to give a biological agent or a JAK inhibitor, another screening should be performed, to the extent considered appropriate.
    • Chest x-ray
    • History of tuberculosis, an IGRA test, as necessary.
    • HBsAg, HBcAb and HCVAb, HIVAgAb, as considered necessary
    • The patient's vaccination status should be established and a pneumococcal conjugate vaccine prescribed, as necessary.

Monitoring of treatment

  • As the individual efficacy and tolerability of drug therapy cannot be predicted, patients should be closely monitored by laboratory tests (see safety monitoring tables T1 and T2) and clinically.
  • Recommendations concerning safety monitoring of antirheumatic medication vary to some extent in different areas. Consult local recommendations.

Monitoring tests for antirheumatic drug therapy. Tests should also be performed 2-3 weeks after any increase in drug dose. ESR and CRP should be checked on visits to the doctor and otherwise as needed.

DrugSafety monitoring tests
Methotrexate
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT
Every 6 monthsCreatinine (in case of impaired renal function, dose reduction)
Hydroxychloroquine
No laboratory monitoring needed. Checkup by an ophthalmologist after 5 years of use
Sulfasalazine
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT
Leflunomide
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT, blood pressure
Note the long biological half-life. Should severe adverse effects occur, treatment should be interrupted and elimination of the drug from the body started (cholestyramine or medicinal charcoal)
Azathioprine
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT
Mycophenolate
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT
Ciclosporin
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsCretinine, blood pressure
Biological antirheumatic drugs and JAK inhibitors
Often used concomitantly with methotrexate in which case monitoring protocol as for methotrexate, and additionally:
Adalimumab, etanercept, golimumab, certolizumab
1 month after initiationBasic blood count with platelets (+ differential count)
Infliximab
Before infusion, as considered appropriate by the physicianBasic blood count with platelets (+ differential count), ALT, CRP
Abatacept
1 month after initiationBasic blood count with platelets (+ differential count), ALT
Tosilizumab and sarilumab
1 month after initiationBasic blood count with platelets (+ differential count), ALT
At 3 monthsLipid levels
Rituximab
Before infusionTests used locally, and IgG monitoring
Tofacitinib and baricitinib
At 3 weeks, 6 weeks, 12 weeks, then every 3-6 monthsBasic blood count with platelets + differential count, ALT
At 3 monthsLipid levels
All drugs
Monitoring tests should also be performed 2-3 weeks after any increase in drug dose.

Interpretation of the results of safety monitoring tests

Safety monitoring testsThreshold values and procedure
Blood testsLeucocytesNeutrophilsLymphocytesPlateletsALT
>3>1.0>0.5>100<2-3 × reference value
If the number of blood cells is below the reference range or ALT is elevated, medication should be reduced as considered necessary. However, mild lymphopenia and macrocytosis commonly occur in association with the use of methotrexate and azathioprine, as do slightly elevated ALT levels during the use of methotrexate, and these require no change to the treatment. If the results of laboratory tests fall outside the ranges specified in the table, medication should be interrupted and tests repeated in 1-2 weeks. Use of the drug can often be continued at lower doses, repeating the monitoring tests. A rheumatologist should be consulted, as necessary. If agranulocytosis develops, the patient should be referred to hospital.

The efficacy of medication should be assessed by a rheumatologist after 3 and 6 months. Before the visits, the following should be tested: basic blood count (complete blood count with differential), creatinine (eGFR, calculator Gfr Calculator), ALT, ALP, ESR, CRP, chemical screening of urine.

One month after starting treatment

  • Visit to a rheumatology nurse or, if necessary, a physician

Three-month visit

  • If remission has not been achieved, medication should be intensified.
  • If methotrexate has been given orally, use of an injectable dosage form should now be started, and if the dose has been below 25 mg, it should be raised to this level now, unless there are contraindications to this.
  • Poor response to treatment, several swollen joints and a high CRP level predict treatment failure. In such cases, a biological agent or a JAK inhibitor should be added to the regimen.

Six-month visit

  • If remission has been achieved, glucocorticoid medication should be gradually reduced.
  • If the patient still has objective signs of arthritis, a biological agent or JAK inhibitor should be started. The EULAR recommendation for management updated in 2016 prefers biological agents because the available safety data covers a longer period of use.

After six months

  • The frequency of monitoring depends on disease activity.
  • If remission has been achieved, follow-up visits should be scheduled for one and two years after the beginning of treatment.
  • If, due to disease activity, major changes have had to be made to the medication or a biological agent or JAK inhibitor has had to be started, follow-up should be started from the beginning again, scheduling visits at 3 and 6 months.

Biological agents Adalimumab for Treating Rheumatoid Arthritis, Certolizumab Pegol for Rheumatoid Arthritis in Adults, Etanercept for the Treatment of Rheumatoid Arthritis, Golimumab for Rheumatoid Arthritis, Rituximab for Rheumatoid Arthritis, Tocilizumab for Rheumatoid Arthritis, Abatacept for Rheumatoid Arthritis, Anakinra for Rheumatoid Arthritis, Infliximab for Rheumatoid Arthritis, Biologics for Rheumatoid Arthritis, Biologics for People with Rheumatoid Arthritis Naive to Methotrexate, Biologics or Tofacitinib for People with Rheumatoid Arthritis Unsuccessfully Treated with Biologics

  • There are no differences in the efficacy of various biological agents, except for anakinra, which is less effective.
  • Any of the following can be given as the first biological agent: TNF-alpha inhibitors (infliximab or its biosimilar, etanercept or its biosimilar, adalimumab or its biosimilar, certolizumab pegol, golimumab), the T-cell inhibitor abatacept or the interleukin 6 inhibitors tosilizumab or sarilumab.
    • The B-cell inhibitor rituximab has specific indications.
  • Biological agents are usually more effective combined with methotrexate than in monotherapy.
  • Antibodies may develop against TNF-alpha inhibitors, except etanercept, which may decrease their efficacy.
    • Methotrexate reduces antibody formation.
    • Unnecessary breaks in medication should be avoided because low drug levels increase the risk of antibody formation.
  • If a patient cannot tolerate methotrexate

JAK inhibitors

  • Oral tofacitinib and baricitinib were the first JAK inhibitors. These should be used with methotrexate but can also be used as monotherapy.
  • In recent-onset rheumatoid arthritis, JAK inhibitors and, of the biological agents, tosilizumab are more effective in monotherapy than methotrexate, whereas the efficacy of other biological agents is no different from that of methotrexate.

If treatment with a biological agent or a JAK inhibitor fails

  • According to the EULAR recommendation, if treatment with a TNF inhibitor fails, treatment can be continued with 1) another TNF inhibitor (particularly if the efficacy decreased after an initially good response) or 2) a biological agent with a different mechanism of action or a JAK inhibitor (if no response was achieved even primarily).
  • If treatment with the second TNF inhibitor fails, it should be continued with a biological agent with a different mechanism of action or with a JAK inhibitor.
  • There is no evidence-based recommendation for any subsequent or other change of medication.

Considerations relating to antirheumatic medication

Risk of infections

Pregnancy and breast-feeding

  • Several restrictions and prohibitions apply concerning antirheumatic drugs. Many drugs need to be discontinued long before conception is planned. Consult a specialist clinic and locally available guidelines to ensure therapy that is also safest possible for the foetus.
  • Inform the patient about the teratogenicity of antirheumatic drugs.

Analgesics Celecoxib for Rheumatoid Arthritis, , , ,

Comorbidities , Bisphosphonates for Steroid Induced Osteoporosis

  • Rheumatic inflammation is an independent risk factor for atherosclerosis.
    • Effective inhibition of inflammation is the most important means of preventing atherosclerosis.
    • Lipid tests to assess the risk of cardiovascular disease should be done when acute inflammation has subsided, i.e. after 3 months of antirheumatic medication, for example.
    • The target lipid levels are the same as in other high-risk patients.
    • Smoking cessation may also have positive effects on the results of treatment of RA.
  • Higher doses of glucocorticoids impair glucose tolerance.
  • Rheumatic inflammation, reduced functional ability and higher glucocorticoid doses make patients susceptible to osteoporosis.
    • In addition, glucocorticoids directly increase the risk of fractures.
    • All patients should be prescribed 1 g calcium + 800 IU vitamin D daily for osteoporosis prophylaxis.
    • At doses of prednisolone exceeding 7.5 mg, bone densitometry and osteoporosis medication should be considered.
    • See the article Osteoporosis Osteoporosis.
  • About one patient in three will develop secondary Sjögren's syndrome.
  • Glucocorticoids precipitate the development of cataracts.

Withdrawal of medication during infections

  • Conventional immunosuppressive antirheumatic drugs (methotrexate, leflunomide, azathioprine and ciclosporin) should be withdrawn for the duration of any infection requiring antimicrobial treatment.
  • Biological agents should be withdrawn for the duration of any generalized infection until the infection has subsided and been confirmed not to be serious.
    • In prolonged bacterial infections, restarting of biological medication can be considered even during antimicrobial medication, as soon as the active infection has subsided.
    • In mild upper respiratory tract infections with no fever, there is no need to withdraw biological medication.
  • Important: The interleukin 6 inhibitors tosilizumab and sarilumab may mask symptoms and findings associated with serious infection and prevent the elevation of CRP levels.

Withdrawal of medication for procedures

  • "Conventional" antirheumatic drugs need not be withdrawn for elective surgery.
  • Even though research results are contradictory, withdrawal of biological agents and JAK inhibitors for elective surgery is recommended, meaning that the agents should be withdrawn for at least 1-2 weeks before operation.
    • Medicines have different half-lives.
  • In the case of endoscopic gastroenterological and gynaecological procedures and other small procedures, such as naevus resection, withdrawal of medication is unnecessary.
  • After uncomplicated surgical procedures, biological medication and JAK inhibitors can usually be restarted when the wound has healed.
  • Biological medication or JAK inhibitors need not be withdrawn for normal filling of dental cavities.
    • There are no guidelines available for procedures possibly causing bacteraemia, such as dental scaling. The procedure can be scheduled between two doses.
    • In the case of more extensive dental surgical procedures or root treatment, the same instructions for temporary withdrawal can be followed as for other types of surgery.

Rehabilitation , , Non-Pharmacological Interventions for Fatigue in Rheumatoid Arthritis, Occupational Therapy for Rheumatoid Arthritis, , , Balneotherapy for Rheumatoid Arthritis, , Psychological Therapies for the Management of Chronic Pain in Adults, , Dynamic Exercise Therapy for Rheumatoid Arthritis, Acupuncture and Electroacupuncture for the Treatment of Rheumatoid Arthritis, ,

  • Physical activity recommendation is an important part of the treatment of RA. Physical exercise improves functional ability.
    • When visiting their doctor, patients should be encouraged to exercise.
    • Exercises may be guided by a physiotherapist, as necessary.
  • Conventional recommendations for health-enhancing physical activity can be given in most cases.
    • At least 2.5 hours of aerobic exercise per week
    • Strength training at least twice weekly
    • Such exercising has no negative effects on disease activity, pain or radiologically observed joint damage.

Aids Assistive Technology for Rheumatoid Arthritis,

  • If joint damage has developed, the patient's functional ability can be improved by using aids supplied by the place of treatment.
    • Wrist splints
    • Support insoles
    • Cervical orthosis
    • Mobility aids
  • The expertise of occupational and physiotherapists should be utilized in matters associated with aids and appliances.

Surgery

  • See article Rheumatoid arthritis surgery Rheumatoid Arthritis Surgery.
  • With improved pharmacological treatment, the need for surgical treatment has considerably decreased.
  • Patients with a long history of the disease may need joint fusion or joint replacement.
  • Destructive rheumatoid arthrosis may be associated with changes in the cervical spine. Atlanto-axial subluxation, which must be borne in mind when administering general anaesthesia, can be seen in flexion radiography of the cervical spine.
    • Subluxation exceeding 10 mm, particularly if associated with neurological symptoms, may require surgical treatment.
  • Disturbing rheumatic nodules and bursae can be removed.

Vaccinations in RA

  • See national or local guidelines on vaccination of adults with rheumatic disease.
  • Live vaccines must not be given during immunosuppressive medication.

Continuity of care Downtitration and Discontinuation Strategies of Tnf-Blocking Agents in Rheumatoid Arthritis

  • If remission is stable, after 2 years follow-up can be transferred to primary health care, where the patient should visit a physician - primarily one familiar with rheumatic diseases - once a year.
  • Patients on biological agents or JAK inhibitors should continue being monitored by a rheumatology unit. If remission is stable, annual visits can be paid alternately to a rheumatology nurse and to a rheumatologist.
  • Antirheumatic medication is normally used for several years or several decades because the symptoms of RA usually recur if medication is withdrawn.
    • If, however, after gradual discontinuation of glucocorticoids the patient's remission is stable for a long time, reduction of medication should be considered.
    • However, total withdrawal of medication is rarely possible. 10-15% of patients with RA achieve long-term remission without medication.
    • If the disease is reactivated when medication is reduced, the medication that previously gave a good response should be resumed.
  • Long-term glucocorticoid treatment may cause adrenocortical suppression Pharmacological Glucocorticoid Treatment.

Follow-up in primary care

  • Cooperation is necessary between the rheumatology outpatient clinic and primary health care.
  • Patients with RA should be followed up annually by a physician - preferably one very familiar with the treatment of the disease.
  • At follow-up visits, the activity of RA should be assessed based on the indicators listed below.
    • Patient's overall assessment of the activity of RA (VAS)
    • Pain (VAS)
    • Functional ability (Health Assessment Questionnaire, HAQ, find out about locally available version)
    • Joints with symptoms
    • Need for analgesics
    • ESR, CRP
    • Joint status: swollen and tender joints, ranges of joint motion
  • What to do if RA is activated
    • Glucocorticoid injections into individual inflamed joints
    • Increased dosage of conventional antirheumatic drugs
    • Low-dose (5-10 mg/day) systemic glucocorticoids, with the dosage later minimized
    • Follow-up to confirm that inflammation can be controlled
    • Consultation of a rheumatologist if the above measures do not correct the patient's status

Evidence Summaries